Sandoz boosts Canadian production capacity

Sandoz boosts Canadian production capacity

Sandoz Canada, a unit of Novartis’ generics arm, has opened a second manufacturing plant at its site in Boucherville, Quebec, boosting local production capacity 66 per cent. The plant, which is due to be fully operational by mid September, comprises manufacturing, laboratory and warehousing space that the firm believes will give it the flexibility it needs to keep pace with increasing market demands. 

Richard Saynor, Head of Commercial Operations for Asia-Pacific, Latin America, Canada and Turkey says that: “The new plant in Boucherville is highly significant for our Canadian operations, and for Sandoz worldwide. It will enable us to triple our production capacity in both vials and ampoules. 

The new plant will manufacture a range of medicines, including opiate analgesics. We currently make 85 different molecules in Boucherville and the plant supplies products globally, although the bulk of sales are in Canada and the US.